Ahmad Abuarqoub, MD
Cardiovascular Disease · Morehead, KYNPI 1568820561
Payments from drug & device makers
What this record shows
26 manufacturers reported payments, led by Abbott at 59.1% of the total. Reporting peaked in 2024 at $6,160 and has fallen 84.6% since, to $951 in 2025.
Across 281 payments — averaging $51.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$8K
- Terumo Medical Corporation$1K
- Novartis$829
- Pfizer$617
- AstraZeneca$572
- Amgen$342
- plus $2K from 20 others
What the payments were for
- Travel & lodging$8,22957%
- Food & beverage$6,12643%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 56 | $8,478 |
| Terumo Medical Corporation | 6 | $1,458 |
| Novartis | 57 | $829 |
| Pfizer | 43 | $617 |
| AstraZeneca | 22 | $572 |
| Amgen | 20 | $342 |
| Penumbra, Inc. | 2 | $339 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $269 |
| Sanofi-aventis U.S. LLC | 3 | $269 |
| Johnson & Johnson | 12 | $234 |
| Cvrx, Inc. | 2 | $180 |
| Kestra Medical Technology Services, Inc. | 3 | $137 |
| Merck | 8 | $136 |
| Boehringer Ingelheim | 6 | $110 |
| Novo Nordisk | 4 | $98 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Atricure, Inc. | 3 | $52 |
| Cook Medical LLC | 4 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Biotronik Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Angiodynamics, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Bridgebio Pharma, Inc. | 1 | $17 |
| Boston Scientific | 1 | $14 |
| Acacia Pharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$2,192
- PERCLOSE PROGLIDE$1,576
- GLIDESHEATH SLENDER$1,326
- Omnilink Elite vascular stent system$1,226
- ASSURITY$928
- SUPERA$779
- Indigo System$339
- ACCENT$249
- ESPRIT$166
- Barostim Neo System$122
- FARXIGA$115
How this compares
$14,355 in reported general payments places this provider in the 85th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 675 | $700,076 |
| EntrestoSacubitril/Valsartan | 224 | $247,463 |
| XareltoRivaroxaban | 118 | $143,431 |
| Repatha SureclickEvolocumab | 154 | $103,250 |
| FarxigaDapagliflozin Propanediol | 61 | $78,975 |
| BrilintaTicagrelor | 89 | $57,041 |
| MultaqDronedarone Hcl | 22 | $31,855 |
| JardianceEmpagliflozin | 15 | $25,268 |
| MounjaroTirzepatide | 23 | $23,081 |
| Praluent PenAlirocumab | 36 | $21,596 |
| OzempicSemaglutide | 12 | $12,709 |
| Dofetilide | 112 | $11,885 |
| Amiodarone Hcl | 260 | $5,896 |
| Ranolazine ErRanolazine | 90 | $5,764 |
| Metoprolol Succinate | 549 | $5,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $617 | $700,076675 claims |
| NovartisEntresto | $829 | $247,463224 claims |
| Johnson & JohnsonXarelto | $234 | $143,431118 claims |
| AstraZenecaFarxiga, Brilinta | $572 | $136,016150 claims |
| Sanofi-aventis U.S. LLCMultaq | $269 | $31,85522 claims |
| Boehringer IngelheimJardiance | $110 | $25,26815 claims |
| Novo NordiskOzempic | $98 | $12,70912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Morehead
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- William SkinnerLexington$312K
- Prabodh MehtaElizabethtown$133K
- John HarrisLouisville$129K
- David MoliternoLexington$115K
- Rohan SamsonLouisville$94K
- Srinivasa AppakonduHazard$91K
- Muhammad AkbarBowling Green$84K
- Jeffrey ReichardFlorence$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.